Journalartikel

Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact


AutorenlisteNickel, J. Curtis; Shoskes, Daniel A.; Wagenlehner, Florian M. E.

Jahr der Veröffentlichung2013

Seiten747-753

ZeitschriftWorld Journal of Urology

Bandnummer31

Heftnummer4

ISSN0724-4983

eISSN1433-8726

DOI Linkhttps://doi.org/10.1007/s00345-013-1062-y

VerlagSpringer


Abstract

The development of an accepted clinical definition, classification system and validated outcome questionnaire for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has led to a flurry of clinical trial activity over the last 15 years.

Twenty-four of these studies enrolled a homogeneous population of CP/CPPS patients, were prospective randomized placebo or sham controlled, and employed the National Institutes of Health chronic prostatitis symptom index (CPSI) as an outcome parameter.

This review of the evidence and clinical impact from these studies suggests that physician's strict adherence to a rigid evidence-based approach for the treatment of a CP/CPPS patient will result in disappointed patients as well as disappointed physicians.

There is no one particular treatment that shows significant clinical efficacy to be recommended as a mono-therapy for CP/CPPS. Therefore, the physician must adapt his knowledge and interpretation of the evidence from randomized placebo- and sham-controlled trials to determine what therapy or therapies are best indicated for each individual patient.




Zitierstile

Harvard-ZitierstilNickel, J., Shoskes, D. and Wagenlehner, F. (2013) Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact, World Journal of Urology, 31(4), pp. 747-753. https://doi.org/10.1007/s00345-013-1062-y

APA-ZitierstilNickel, J., Shoskes, D., & Wagenlehner, F. (2013). Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact. World Journal of Urology. 31(4), 747-753. https://doi.org/10.1007/s00345-013-1062-y



Schlagwörter


ALFUZOSINChronic pelvic pain syndromeCHRONIC PROSTATITISDOUBLE-BLINDEvidence basedLEVOFLOXACINMENMONOTHERAPYmultimodal therapyPLACEBO-CONTROLLED MULTICENTERRandomized placebo-controlled trialsSYMPTOM INDEXTAMSULOSIN


Nachhaltigkeitsbezüge


Zuletzt aktualisiert 2025-21-05 um 18:38